Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Abstract

To provide formulations for orally administered poorly permeable molecules, which is highly beneficial for patients who require multiple daily doses, by overcoming at least this low permeability to the intestinal membrane and overcoming, for some of these molecules, particularly peptides and proteins, the chemical and physical instability in the gastrointestinal tract, specifically the loss of activity due to the acidic conditions in the stomach, and the enzymatic degradation throughout the intestine.SOLUTION: Applicants have developed a pharmaceutical formulation intended for oral delivery of a synthetic or natural poorly permeable molecule or a salt / solvate thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable molecule or a salt or solvate thereof in an amount of 0.01 to 10 wt.% of the total weight of the formulation; a lipophilic phase comprising a triglyceride of a fatty acid in an amount of 50 to 80 wt.% of the total weight of the formulation; and at least one lipophilic surfactant comprising a partial ester of a polyol and a fatty acid in an amount of about 10 to 50 wt.% of the total weight of the formulation.SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 832,508, filed April 11, 2019, the entire contents of which are incorporated herein by reference.

[0002] The present disclosure relates to formulations for oral delivery of poorly permeable proteins, peptides, and small molecules. More specifically, the present disclosure relates to pharmaceutical formulations intended for oral delivery of any poorly permeable synthetic or natural molecule having therapeutic activity, or a salt or solvate thereof. [Background technology]

[0003] Poorly permeable molecules are compounds that are poorly absorbed through the intestinal membrane. Therefore, they are administered intravenously or subcutaneously. Due to poor absorption through the intestinal membrane, their clinical use is very limited when they need to be administered IV and several times a day (e.g., insulin for diabetes). These poorly permeable compounds are identified as BCS class III and class IV compounds in the classification proposed by Amidon GL et al., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability (Pharm Res. March 1995; 12(3):413-20), which is incorporated herein by reference in its entirety. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Patent No. 9,259,389 [Patent Document 2] CA2439366 [Non-patent literature]

[0005] [Non-Patent Document 1] Amidon GL et al., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability (Pharm Res. March 1995; 12(3):413-20) [Non-Patent Document 2] ICH Harmonized Tripartite Guideline ICH Q3B dated June 2, 2006 (Impurities in New Drug Products) [Non-Patent Document 3] FDA Guidance for Industry, dated August 3, 1999, ANDAS: Blend Uniformity Summary of the Invention [Problem to be solved by the invention]

[0006] The applicants have developed formulations for poorly permeable molecules to be administered orally. These formulations are very beneficial for patients who require several doses per day. To prepare such formulations for oral delivery of poorly permeable molecules, the applicants had to overcome at least this poor permeability to the intestinal membrane and, for some of these molecules, especially peptides and proteins, to overcome the chemical and physical instability in the digestive tract, specifically the loss of activity due to the acidic conditions in the stomach, and the enzymatic degradation throughout the intestine. Therefore, the applicants have developed a delayed release coated agent that can deliver poorly permeable molecules in the intestine with the in-situ generation of a permeation enhancer that enhances their bioavailability.

[0007] In US Patent No. 9,259,389, the inventors found that digestible inverse emulsions can enhance the bioavailability of oligosaccharides. Unexpectedly, the applicants found that a solution of lipid additive with a poorly permeable molecule dispersed as a powder in the formulation allows better bioavailability results for this particular class of molecules (i.e., BCS class III and class IV compounds in the classification proposed by Amidon GL et al. (Pharm Res. March 1995; 12(3):413-20)). In particular, the applicants found that for poorly permeable molecules, specifically BCS class III protein and peptide compounds, a formulation without added water can be beneficial. Without being bound to any theory, it is believed that water tends to cause this class of poorly permeable molecules to aggregate together. More specifically, the applicants found that when water was omitted from a formulation comprising a solution of a lipid-based additive having a protein or peptide molecule or salt of class III of the BCS with low permeability dispersed as a powder in the formulation, higher bioavailability results were achieved with this particular class of molecule. In contrast, the removal of water was detrimental for the sugars of U.S. Pat. No. 9,259,389.

[0008] In addition, applicants can increase drug loading if they can disperse the active pharmaceutical ingredient ("API") as a powder without the need to solubilize the API in water when solubilization is not required. Furthermore, the formulation is inherently more physically stable because the lipid additive can be in solution as a single phase. Thus, it may not be necessary to add a stabilizer such as silicon dioxide to stabilize the phase. In some embodiments, a thickener can be added for manufacturing purposes to maintain homogeneity of the API powder in the suspension during the process. In some embodiments, the thickener can be silicon dioxide. Finally, compared to other formulations found in the literature that use additives such as penetration enhancers, the formulations disclosed herein can be used with the public's recognition that they are safe additives or ingredients that are already commercially available. [Means for solving the problem]

[0009] In some embodiments, the pharmaceutical formulation comprises a synthetic or natural poorly permeable molecule or a salt or solvate thereof in an amount of 0.01-20 wt% of the total mass of the formulation; a lipophilic phase comprising a triglyceride of a fatty acid in an amount of 50-80 wt% of the total mass of the formulation; and at least one lipophilic surfactant comprising a partial ester of a polyol and a fatty acid in an amount of 10-50 wt% of the total mass of the formulation. In some embodiments, the synthetic or natural poorly permeable molecule or a salt or solvate thereof is a compound of class III or class IV of the BCS. In some embodiments, the synthetic or natural poorly permeable molecule is a peptide or a protein. In some embodiments, the peptide has 5-20 amino acids. In some embodiments, the formulation comprises at least one hydrophilic surfactant having a hydrophilic-lipophilic balance ("HLB") of more than 10 in an amount of 1-30 wt% of the total mass of the formulation. In some embodiments, the at least one hydrophilic surfactant is selected from the group consisting of polyoxyethylene (20) monooleate, PEG 8 caprylic / capric glyceride, PEG 6 caprylic / capric glyceride, poly(oxyethylene) (4) lauryl ether, and mixtures thereof. In some embodiments, the fatty acid triglyceride is a medium chain fatty acid. In some embodiments, the lipophilic surfactant comprises a mixture of monoglycerides and diglycerides of medium chain fatty acids. In some embodiments, the formulation does not include water. In some embodiments, the delayed release pharmaceutical agent comprises any of the above-mentioned formulations, wherein the delayed release agent is a coated agent whose release is pH-dependent. In some embodiments, the method for treating a patient comprises administering an effective amount of any of the above-mentioned formulations to a person in need thereof.

[0010] Additional advantages will be readily apparent to those skilled in the art from the following detailed description.The examples and descriptions herein are intended to be illustrative in nature and not limiting.

[0011] All publications, including patent documents, scientific articles, and databases, referenced in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. To the extent that the definitions set forth herein are contrary to or inconsistent with the definitions set forth in the patents, applications, published applications, and other publications incorporated herein by reference, the definitions set forth herein take precedence over the definitions incorporated herein by reference. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present disclosure relates to pharmaceutical formulations intended for oral administration that contain a therapeutically active synthetic or natural poorly permeable molecule, or a pharma- ceutically acceptable salt or solvate thereof. These formulations may be lipid-based formulations. In addition, these formulations may be delayed release agents. In some embodiments, the agent may be a delayed release soft gel capsule, hard capsule, or a combination thereof. In some embodiments, the delayed release agent may be an enteric release agent.

[0013] The formulation may include: (A) a synthetic or natural poorly permeable molecule; (B) a lipophilic phase; (C) at least one lipophilic surfactant; and / or (D) at least one hydrophilic surfactant. In some embodiments, the formulation may include chemical and / or physical stabilizers.

[0014] Low permeability molecules, synthetic or natural In some embodiments, the formulation may comprise a synthetic or natural poorly permeable molecule, or any pharma- ceutically acceptable salt of such poorly permeable molecules, in an amount of up to about 1 wt%, about 2 wt%, about 5 wt%, about 10 wt%, about 15 wt%, or about 20 wt% of the total mass of the formulation. In some embodiments, the formulation may comprise a synthetic or natural poorly permeable molecule, or any pharma- ceutically acceptable salt of such poorly permeable molecules, in an amount of about 0.01-30 wt%, about 0.1-30 wt%, about 0.01-20 wt%, about 0.1-20 wt%, about 0.1-15 wt%, about 0.1-10 wt%, about 0.1-5 wt%, about 0.1-2 wt%, about 0.1-1 wt%, about 0.1-0.5 wt%, or about 0.5-1.5 wt% of the total mass of the formulation.

[0015] The synthetic or natural poorly permeable molecules, or pharma- ceutically acceptable salts thereof, may include any poorly permeable protein, polypeptide, peptide, or small molecule intended for oral delivery, and the active ingredient according to the invention may be, but is not limited to, insulin, human growth hormone, calcitonin (e.g. salmon calcitonin), interferons such as α-, β-, or γ-interferon, glucagon, gonadotropin releasing hormone, enkephalin, vaccines, enzymes, hormone analogs, enzyme inhibitors, antibodies, and antibody mimetics. The synthetic or natural poorly permeable molecules, or pharma-ceutically acceptable salts thereof, are those identified as class III and class IV of the BCS in the classification proposed by Amidon GL et al., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability (Pharm Res. 1995 March; 12(3):413-20).

[0016] lipophilic phase In some embodiments, the formulation may comprise a lipophilic phase in an amount of up to about 50 wt%, about 55 wt%, about 60 wt%, about 65 wt%, about 70 wt%, or about 80 wt% of the total weight of the formulation, in some embodiments, the formulation may comprise a lipophilic phase in an amount of about 50-80 wt%, about 55-75 wt%, about 60-70 wt%, about 62-68 wt%, about 64-66 wt%, or about 65 wt% of the total weight of the formulation.

[0017] In some embodiments, the lipophilic phase may be a triglyceride of a fatty acid. A triglyceride of a fatty acid may refer to any triglyceride of a pharma- ceutical, orally acceptable, saturated or unsaturated fatty acid. In some embodiments, the triglyceride of a fatty acid may be represented by the following formula:

[0018] [ka]

[0019] (wherein R1, R2, and R3 each independently represent an alkyl or alkenyl group of a parent fatty acid). may have.

[0020] The fatty acids can be saturated or unsaturated. In particular, the fatty acids can be saturated, since unsaturated fatty acids can lead to a slower rate and lower digestibility. Some common saturated fatty acids are shown in Table 1 below.

[0021] [Table 1]

[0022] R1, R2, and R3 may represent linear or branched chains. In some embodiments, R1, R2, and R3 may be C3-C23 alkyl or alkenyl groups, C5-C13 alkyl or alkenyl groups, or C7-C9 alkyl or alkenyl groups. In some embodiments, the fatty acids are saturated and medium chain fatty acids. Thus, the lipophilic phase may be triglycerides of long chain (e.g., soybean oil and fish oil), medium chain, or short chain (e.g., glyceryl triacetate) fatty acids. In some embodiments, the triglycerides may be of caprylic acid, capric acid, or mixtures thereof (e.g., the commercial products Miglyol 812®, Captex 355®, Estasan®, Neobee M5®, Labrafac CC®, and Captex 1000®). In some embodiments, the triglyceride can be a triglyceride of C6 to C12 fatty acids or a C8 to C10 fatty acids.

[0023] Lipophilic Surfactants In some embodiments, the formulation may include at least one lipophilic surfactant in an amount of up to about 1 wt%, about 5 wt%, about 10 wt%, about 15 wt%, about 20 wt%, about 25 wt%, about 30 wt%, about 35 wt%, about 40 wt%, about 45 wt%, or about 50 wt% of the total mass of the formulation. In some embodiments, the formulation may include at least one lipophilic surfactant in an amount of about 10-50 wt%, about 15-35 wt%, about 20-30 wt%, about 22-28 wt%, about 24-26 wt%, or about 25 wt% of the total mass of the formulation. If the formulation includes less than about 10 wt% of at least one lipophilic surfactant, dynamic digestion may not be optimized. When the formulation contains more than 50 wt% of at least one lipophilic surfactant, the amount of lipophilic phase available for release of sodium caprate may not be optimal.

[0024] In some embodiments, the at least one lipophilic surfactant may be a partial ester of a polyol and a fatty acid. A partial ester of a polyol and a fatty acid may refer to any partial ester obtained by esterification of a pharma- ceutical and orally acceptable polyol and a saturated or unsaturated fatty acid. Common saturated fatty acids are shown in Table 1 above. The fatty acid may be a medium chain fatty acid such as a C6-C12 fatty acid, in particular caprylic acid and / or capric acid. The polyol may be, for example, propylene glycol and glycerol. For example, the partial ester of a polyol and a fatty acid can be a propylene glycol monoester and / or diester of a fatty acid (e.g., propylene glycol monolaurate sold under the trade name Lauroglycol®, propylene glycol monomyristate sold under the trade name Mirpyl®, or propylene glycol dicaprylate / dicaprate sold under the trade name Captex 200®, Miglyol 840®, or Neobee M-20®), and / or a polyglycerol ester of a fatty acid (e.g., polyglyceryl oleate sold under the trade name Plurol Oleique® or Drewpol 10.10.10®, or polyglyceryl mixed fatty acids sold under the trade name Caprol ET®).

[0025] The at least one lipophilic surfactant may be a partial ester of propylene glycol and fatty acids (e.g., the commercial products Capryol PGMC® and Capmul PG-8®). In some embodiments, the at least one lipophilic surfactant may be a mixture of mono- and diglycerides of fatty acids, a mixture of mono- and diglycerides of medium chain fatty acids, a mixture of mono- and diglycerides of caprylic and / or capric acid (e.g., the commercial products Capmul MCM and Capmul MCM C8®, Imwitor 988®, Imwitor 742®), or a mixture of mono- and diglycerides of capric acid (e.g., the commercial products Capmul MCM C100 or Imwitor 308®).

[0026] In some embodiments, the at least one lipophilic surfactant can be a lecithin, such as, but not limited to, soybean lecithin.

[0027] Hydrophilic Surfactants In some embodiments, the formulation may include at least one hydrophilic surfactant in an amount of up to about 2 wt%, about 5 wt%, about 8 wt%, about 10 wt%, about 15 wt%, about 20 wt%, about 25 wt%, or about 30 wt% of the total weight of the formulation. In some embodiments, the formulation may include at least one hydrophilic surfactant in an amount of about 0-30 wt%, about 0-15 wt%, about 0-10 wt%, about 1-30 wt%, about 5-15 wt%, about 8-12 wt%, about 9-11 wt%, or about 10 wt% of the total weight of the formulation. If the amount of at least one hydrophilic surfactant is more than about 30 wt% of the formulation, the amount of lipophilic phase available for the release of sodium caprate may be compromised.

[0028] In some embodiments, the at least one hydrophilic surfactant can be any hydrophilic surfactant that is pharma- ceutical and orally acceptable and has a hydrophilic-lipophilic balance ("HLB") value greater than 10. The HLB value is an empirical parameter commonly used by those skilled in the art to characterize the relative hydrophilicity and lipophilicity of nonionic surfactants.

[0029] In some embodiments, the at least one hydrophilic surfactant is a phospholipid; a polyoxyethylene sorbitan fatty acid derivative, such as polyoxyethylene (20) monolaurate (sold under the trade name Tween 20®), polyoxyethylene (20) monooleate (sold under the trade name Tween 80® and / or Crillet 4®), or polyoxyethylene (20) monopalmitate (sold under the trade name Montanox 40®); a castor oil or hydrogenated castor oil ethoxylate with an HLB value of more than 10, such as polyoxyethylene (35) castor oil (sold under the trade name Cremophor EL®), polyoxyethylene (40) hydrogenated castor oil (sold under the trade name Cremophor RH40®), polyoxyethylene (40) castor oil (sold under the trade name Etocas 40®), or polyoxyethylene (60) hydrogenated castor oil (sold under the trade name Nikkol HCO-60®); fatty acid ethoxylates with an HLB value of more than 10, such as polyoxyethylene (8) stearate (sold under the trade name Myrj 45®), polyoxyethylene (30) monolaurate (sold under the trade name Tagat L®), polyoxyethylene (20) stearate (sold under the trade name Marlosol 1820®), or polyoxyethylene (15) oleate (sold under the trade name Marlosol OL15®); alcohol ethoxylates with an HLB value of more than 10, such as polyoxyethylene (10) oleyl ether (sold under the trade name Brij 96®), polyoxyethylene (15) oleyl ether (sold under the trade name Volpo 015®), polyoxyethylene (30) oleyl ether (sold under the trade name Marlowet OA30®), or polyoxyethylene (20) C12-C14 fatty ethers (sold under the trade name Marlowet IMA20®); polyoxyethylene-polyoxypropylene copolymers and block copolymers with an HLB value of more than 10, such as the product sold under the trade name Syperonic PE L44® with an HLB value of 16 or the product sold under the trade name Syperonic F127® with an HLB value of 22;It may be an anionic surfactant, such as sodium lauryl sulfate, sodium oleate or dioctyl sodium sulfosuccinate, or an alkylphenol surfactant with an HLB value of more than 10, such as polyoxyethylene (9-10) nonylphenol (sold under the trade name Triton N-101®), or polyoxyethylene (9) nonylphenol (sold under the trade name Synperonic NP9®); Vitamin E; D-alpha-tocopheryl polyethylene glycol succinate (TPGS); or PEG 15 hydroxystearate (sold under the trade name Solutol HS15®);

[0030] In some embodiments, the at least one hydrophilic surfactant is a polyethoxylated surfactant. In some embodiments, the at least one hydrophilic surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, and polyoxyethylene esters of fatty acids, such as glycerol and polyoxyethylene esters of fatty acids. In some embodiments, the fatty acids are saturated or unsaturated. Common saturated fatty acids are listed in Table 1 above. In some embodiments, the fatty acids are medium chain fatty acids such as C6-C12 fatty acids (e.g., lauric acid, caprylic acid, and / or capric acid).

[0031] In some embodiments, the number of ethylene oxide group units in the surfactant may be between 4 and 20. In some embodiments, the at least one hydrophilic surfactant may be selected from the group consisting of polyoxyethylene (20) monooleate (e.g., commercially available Tween 80®), PEG 8 caprylic / capric glyceride (e.g., commercially available Labrasol®), PEG 6 caprylic / capric glyceride (e.g., commercially available Softigel 767®), poly(oxyethylene (4) lauryl ether (e.g., commercially available Brij 30®), and mixtures thereof.

[0032] hydrophilic solvent In some embodiments, the formulation may include at least one anhydrous hydrophilic solvent in an amount of up to about 15 wt%, about 10 wt%, about 5 wt%, or about 1 wt% of the total mass of the formulation to help solubilize the API. In some embodiments, the formulation does not include at least one hydrophilic solvent. In some embodiments, at least one hydrophilic solvent is added, for example, to solubilize a viscosity enhancing agent.

[0033] In some embodiments, the at least one hydrophilic solvent can be selected from the group consisting of propylene glycol, PEG 400 diethylene glycol monoethyl ether, glycerol triacetate, ethanol, glycerol, dimethyl isosorbide, N-methyl-2-pyrrolidone, poloxamer, and mixtures thereof.

[0034] Chemical and / or physical stabilizers In some embodiments, the formulation may include at least one chemical and / or physical stabilizer in an amount of up to about 25 wt% of the total mass of the formulation. In some embodiments, a physical stabilizer may be added to maintain the uniformity of the suspension of the API powder during processing. As described below, the placebo formulation is physically stable when it is a single phase consisting of lipid additives in solution, but a thickening agent is added because the API powder is dispersed to maintain homogeneity as a suspension.

[0035] The chemical and / or physical stabilizer may be any pharmaceutical ingredient that improves the chemical stability of poorly permeable molecules in the formulation or improves the physical stability of poorly permeable molecule formulations in order to comply with the requirements of the ICH Harmonized Tripartite Guideline ICH Q3B (Impurities in New Drug Products) dated June 2, 2006, current Step 4 version.

[0036] In some embodiments, the chemical stabilizer can be a lipophilic surfactant. For example, the chemical stabilizer can be an ester of acetic acid, succinic acid, lactic acid, citric acid, and / or tartaric acid of mono- and / or diglycerides of fatty acids, such as distilled acetylated monoglycerides (sold under the trade name Myvacet 9-45®), caprylic / capric diglyceryl succinate (sold under the trade name Miglyol 829®), mono / di-succinylated monoglycerides (sold under the trade name Myverol SMG®), glyceryl stearate citrate (sold under the trade name Imwitor 370®), glyceryl monostearate / citrate / lactate (sold under the trade name Imwitor 375®), or diacetyl tartaric acid esters of monoglycerides (sold under the trade name Cordatem®). T22®); acid ester ethoxylates formed by reacting ethylene oxide with fatty acids or glycerol esters of fatty acids having an HLB value of less than 10, such as polyoxyethylene (4) laurate (sold under the trade name Crodet 04®), polyoxyethylene (2) stearate (sold under the trade name Cithrol 2MS®), polyoxyethylene (3) stearate (sold under the trade name Marlosol 183®), or glyceryl 12 EO dioleate (sold under the trade name Marlowet G12DO®); sorbitan esters of fatty acids, such as sorbitan monolaurate (sold under the trade name Span 20® or Crill 1®), or sorbitan monooleate (sold under the trade name Crill 4®); transesterification products of triglycerides of natural or hydrogenated vegetable oils and polyalkylene polyols having an HLB value of less than 10, such as polyoxyethylated apricot kernel oil (apricot kernel oil). kernal oil (sold under the trade name Labrafil M1944CS®), polyoxyethylated corn oil (sold under the trade name Labrafil M2125CS®), or polyoxyethylated hydrogenated oil (sold under the trade name Gelucire 37 / 06®);Or it may be an alcohol ethoxylate with an HLB value of less than 10, such as polyoxyethylated (3) oleyl ether (sold under the trade name Volpo N3®), polyoxyethylated (2) oleyl ether (sold under the trade name Brij 93®), or polyoxyethylated (4) lauryl ether (sold under the trade name Marlowet LA4®);

[0037] In some embodiments, the chemical stabilizer can be a buffering agent, such as a citrate, phosphate, or acetate buffer, and / or a thickening agent, such as partially hydrogenated oils, hydrogenated oils, or monoesters of unsaturated or saturated fatty acids, polyvinylpyrrolidone derivatives, polyethylene oxide.

[0038] In some embodiments, the physical stabilizer is silicon dioxide. In some embodiments, the silicon dioxide can be colloidal silicon dioxide. Colloidal silicon dioxide is also known as fumed silicon dioxide, silica fume, or pyrogenic silica. Such silicon dioxide is commercially available under the trademarks Aerosil® (Evonik Industries), Cab-O-Sil® (Cabot Corporation), and Wacker HDK® (Wacker-Chemie GmbH).

[0039] In some embodiments, the formulation may include a lipid thickener. Examples of lipid thickeners include, but are not limited to, Akosoft 36, Geleol, Gelucire, Koliwax, hydrogenated oils, or combinations thereof. In some embodiments, the formulation may include a lipid thickener in an amount of about 5-25 wt%, about 10-20 wt%, about 12-18 wt%, about 14-16 wt%, or about 15 wt% of the total weight of the formulation.

[0040] In some embodiments, the formulation may include povidone. Examples of povidone may include different grades of povidone, such as K30 or K90. In some embodiments, the formulation may include povidone in an amount of about 0.5-10 wt%, about 1-10 wt%, about 2-8 wt%, about 4-6 wt%, or about 5 wt% of the total weight of the formulation.

[0041] Formulation In some embodiments, the formulation may be liquid in the form of a solution. In some embodiments, the formulation is a solution in which a poorly permeable molecule (e.g., API) is suspended in the formulation as a powder. In some embodiments, the formulation may be an anhydrous inverse microemulsion or an anhydrous inverse emulsion. In some embodiments, the formulation is homogenous. A homogenous formulation is one that meets the requirements of the FDA Guidance for Industry dated August 3, 1999, ANDAS: Uniformity of Blends for the Manufacture of Bulk Filled Dosage Forms and / or the Content Uniformity Testing Criteria (Assessment of Mass Variation - European Pharmacopoeia, Uniformity of Dosage Units 2.9.40, USP General Chapter <905> The formulation may be any single or multi-phase formulation that can be used to manufacture a viable final pharmaceutical agent in accordance with the Pharmaceutical and Medical Devices Act, 2003 (excluding 6.02 uniformity of dosage units) and / or can meet compliance with assay results for stable drug substance in stratified samples obtained throughout the manufacturing process.

[0042] The formulations disclosed herein can be prepared according to the following process. The formulation can be a blend of different additives. In some embodiments, the minimal amount of additives can be added at the beginning and the thickener can be added towards the end before adding the API. In some embodiments, the formulation is a clear solution and the API (i.e., the low permeability molecule or its salt) is suspended in the formulation as a powder. The API can be a pure API crystal that is milled by any method known to those skilled in the art to obtain a solid API, such as micronization, freeze drying, spray drying, or atmospheric spray freeze drying. It can also be an API in a mixture with a solid component to obtain a solid API, such as a glucoside derivative, a cellulose derivative, or adsorbed to another additive, such as mesoporous silica, nanotubes, or any material that has adsorption properties or the API can be complexed, such as, but not limited to, complexed with an ion exchange resin.

[0043] The formulations disclosed herein can be digestible. Thus, glycerides can be de-esterified to 2-monoglycerides and free fatty acids by pancreatic lipase in GI fluids. The formulations can release sodium caprate, which can act as a penetration enhancer to promote absorption of poorly permeable molecules contained in the formulation. Pancreatic lipase in the presence of colipase can catalyze the lipolysis (also called hydrolysis or de-esterification) of emulsified oils to produce fatty acids. The rate of fatty acid production, and therefore the rate of lipolysis, can be measured via continuous titration using a pH stat, as described in U.S. Patent No. 9,259,389, the entirety of which is incorporated herein by reference. The extent of digestion after 120 minutes with a pancreatin solution containing a pancreatin extract having an activity of approximately 8 Tributyrin Units (TBU) per mg of dry powder in distilled water at a dose of 250 mg / ml at 37.5° C.+ / -0.5° C. can be such that at least about 1 mmol, about 1.5 mmol, or about 1.7 mmol of total free fatty acids are released from the formulations disclosed herein.

[0044] In some embodiments, the extent of digestion (and therefore the rate of digestion) after 120 minutes in the CPS model is such that at least about 0.2 mmol, about 0.4 mmol, about 0.6 mmol, or about 0.7 mmol of C10 fatty acid (i.e., capric acid) is released from the formulations disclosed herein.

[0045] In some embodiments, the formulations disclosed herein are liquid or semi-solid (i.e., have a melting temperature in the range above room temperature) and can be orally administered to a patient in need thereof using pharmaceutical agents known to those skilled in the art. Such pharmaceutical agents can be gelatin or non-gelatin hard or soft gel capsules. Such capsules can include hard and soft gelatin capsules, as well as combinations thereof (e.g., overencapsulation of soft gelatin capsules with hard gelatin capsules or non-gelatin soft and / or hard capsules). The formulations can also be translated into conventional solid formulations by techniques known to those skilled in the art, such as adsorption, hot melt granulation / coating, and / or by selected carriers, diluents, additives, and / or binders.

[0046] The site of absorption of poorly permeable molecules may be in the intestine. Therefore, it is advantageous to simultaneously deliver the formulation and the poorly permeable molecule to the site of absorption and the place where the formulation is digested. In this case, dilution of the formulation in the stomach must be avoided. As a result, in some embodiments, the pharmaceutical agent is a delayed release agent containing the formulation disclosed herein. Various drug delivery systems can be envisioned by those skilled in the art to obtain a delayed release agent. Various materials make it possible to obtain a delayed release agent. These materials can be used to obtain a matrix form (for example as described in CA2439366) or a coated form. Some delayed release and protection results can be obtained using a coated agent.

[0047] The various types of materials that can be used to prepare delayed release agents are: polymers that are sensitive to intestinal enzymes such as esterases and lipases (e.g. salol, shellac, lipidic compounds (stearic acid, partial glycerides), carnauba wax, hydrogenated castor oil) or proteases (e.g. keratin, gluten, zein); polymers that are soluble at intestinal pH (this option is the most widely used in the pharmaceutical industry). These polymers can be polysaccharides, such as pectin, cellulose, or starch derivatives. For example, cellulose acetophtalate, hydroxypropylmethylcellulose, cellulose acetohemisuccinate, starch and amylose acetophthalate; vinyl derivatives (e.g. polyvinyl acetate, polyvinyl acetophthalate); acrylic derivatives (e.g. Eudragit L, Eudragit FS30D); or maleic acid copolymers.

[0048] The delayed release pharmaceutical agent is pH dependent, so that a polymer that is soluble at intestinal pH can be used. In some embodiments, the delayed release pharmaceutical agent can be an enteric agent, particularly an enteric capsule as an enteric soft gelatin capsule or an enteric hard capsule, more particularly an enteric oval soft gelatin capsule, even more particularly an enteric 7.5 oval or smaller soft gelatin capsule. In some embodiments, the gelatin capsule has a hardness of 8-12N, particularly 9.5N, according to the test shown below. Smaller agents can be even more convenient for delivering low permeability to the intestine. Delayed release agents with a size of 3mm or less can pass the entrance of the pylorus faster than larger agents and then release low permeability molecules faster in the intestine after absorption by the patient. In this case, the dosage for administration may require an agent consisting of several small agents swallowed at the same time.

[0049] The manufacture of enteric coated soft gelatin capsule formulations is well known to those of skill in the art, as described in US Pat. No. 9,259,389, which is incorporated herein by reference in its entirety.

[0050] The final delayed release pharmaceutical agent can be monolithic or multiparticulate. This means that both the final dosage form (hard capsule, soft gel capsule, or other dosage form) and the intermediate product (pellets, granules, etc.) can be coated. Certain agents can be in multiparticulate form (coated pellets, granules filled into a hard capsule, or pellets used to form several mini-tablets) to minimize inter-individual variability. Examples of reversible agents for enteric coating that may be associated with acrylic derivatives (e.g. Eudragit L) are: glycerol, propylene glycol, sorbitol, sorbitol / sorbitan blends, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl citrate, triacetin, acetylated monoglyceride 9-45, polyethylene glycol.

[0051] therapeutic activity The formulations disclosed herein can have the same therapeutic activity as the poorly permeable molecule or its salt contained therein. Thus, the present disclosure also relates to the enteric coated pharmaceutical formulations disclosed herein for use as a drug.

[0052] The term "therapeutically effective amount" as used herein can refer to the amount of an agent required to treat, ameliorate, or prevent a targeted disease state, or to exhibit a detectable therapeutic or prophylactic effect. In general, a therapeutically effective amount can be estimated based on available data for parenteral administration of a product in humans.

[0053] Effective doses of the compounds disclosed herein may be ascertained by conventional methods. The specific dosage level required for any particular patient will depend on several factors, including the severity of the condition being treated, the patient's general health (i.e., age, weight, and diet), the patient's sex, the time and frequency of administration, and the tolerance / response to the therapy. In general, however, the daily dose (whether administered in a single dose or in divided doses) will range from 1 to 1000 mg per day, most commonly 5 to 200 mg per day. Alternatively, dosages can be administered per unit body weight, in this example, typical doses are 0.01 μg / kg to 50 mg / kg, particularly 10 μg / kg to 10 mg / kg, 50 μg / kg to 2 mg / kg. EXAMPLES

[0054] Exemplary compositions of the formulations disclosed herein can be found in Table 2 below.

[0055] [Table 2]

[0056] The API in the above formulation was a peptide of five amino acids with a molecular weight of about 700 g / mol. In the above formulation, Miglyol, Capmul, and triethyl citrate are permeation enhancers, and Tween and Kolliphor EL are surfactants that aid in digestive motility and then improve the effect of Miglyol and Capmul. Water, PEG 400, and propylene glycol solubilize the API but have no permeability activity. The formulation is designed to affect low permeability of the molecule to the intestinal membrane. Loss of activity due to chemical and physical instability in the digestive tract and acidic conditions inside the stomach can be controlled by coating.

[0057] Formulations 1-4 (F1-F4) were prepared as described in U.S. Pat. No. 9,259,389 and were used as comparators to validate the improved bioavailability provided by the invention disclosed herein.

[0058] Preparation of Formulation 1: The amount of API is first dissolved in water, then Tween 80 is added. The resulting mixture is stirred to obtain a homogeneous solution. Then, a solution of Miglyol 812N and Capmul MCM in a given ratio (see table 2) is added to the previous mixture. The final emulsion is stirred at room temperature until a homogeneous mixture (no phase separation, API completely solubilized) is obtained. This formulation should be stabilized by silicon dioxide.

[0059] Preparation of Formulation 2: This formulation encompasses the inventive formulation. Capmul MCM and Miglyol 812N in a selected ratio are mixed together at room temperature. Then, Tween 80 in a given amount is added to the solution. The resulting mixture is homogenized under stirring at room temperature. The API amount is added last and the final mixture is stirred until it has a homogenous suspension (no phase separation, API is well dispersed in the formulation).

[0060] Preparation of Formulation 3: This formulation is another solution of API with a much lower digestibility but with another penetration enhancer (triethyl citrate). The amount of API is first dissolved in a solution of PEG400 and propylene glycol, then triethyl citrate and Kolliphor EL are added. Capmul MCM is added last. The resulting mixture is stirred at room temperature to obtain a homogenous solution (no phase separation, API completely solubilized).

[0061] Preparation of Formulation 4: Capmul MCM and Miglyol 812N in a selected ratio are mixed together at room temperature. Tween 80 and triethyl citrate in a given amount are then added sequentially to the solution. The resulting mixture is homogenized under stirring at room temperature. The API amount is added last and the final mixture is stirred until a homogenous suspension (no phase separation, API well dispersed in the formulation) is obtained.

[0062] Digestibility of the formulations disclosed herein With respect to the digestible component (Miglyol 812N and Capmul MCM) ratio, over 85% of formulation 1 (inverse emulsion) and formulation 2 (API in suspension) are highly digestible. After 30 minutes of digestion, formulation 1 releases 2.3 mmol of fatty acids per gram of formulation, and formulation 2 releases 2.1 mmol of fatty acids per gram of formulation. After 3 hours, the maximum amount of fatty acids released by formulations 1 and 2 is about 2.8 mmol of fatty acids per gram of formulation, which is the maximum release possible for all four formulations. More than 75% of fatty acids are released in less than 30 minutes for these two formulations. Formulation 3 (API in solution) without triglyceride (Miglyol 812N) releases the least amount of fatty acids: 0.6 mmol of fatty acids per gram of formulation after 3 hours of digestion. After 30 minutes of digestion, it releases only 0.3 mmol (50%) of fatty acids per gram of formulation. Formulation 4 releases an intermediate amount of fatty acids compared to the other three (2.0 mmol of fatty acids per gram of formulation after 3 hours of digestion), resulting in a level of digestible components of approximately 70%. 1.7 mmol of fatty acids are released after 30 minutes, which corresponds to approximately 85% of the release within 30 minutes.

[0063] Table 3 below shows the bioavailability of a five amino acid peptide of approximately 700 Da, which is not susceptible to enzymatic degradation and was included in the formulations disclosed herein after administration to dogs.

[0064] [Table 3]

[0065] Pharmacokinetic studies following intraduodenal administration of formulations in dogs were conducted using non-naive male beagle dogs (6.5-10 kg) to determine the bioavailability of poorly permeable molecules when delivered in a formulation according to the invention. To do this, the compounded formulations were administered endoscopically under anesthesia.

[0066] Animals were anesthetized using an intramuscular injection of 0.03 mL / kg Rompun followed by an intramuscular injection of 0.1 mL / kg Zoletil 100® or any similar drug.

[0067] Test formulations were delivered into the duodenum (at least 4 cm behind the pyloric sphincter) using a plastic syringe fitted with a catheter that passed through the central lumen of the endoscope while the animals lay on their left side during the endoscopy. The dose of poorly permeable molecule administered was adjusted to each dog's body weight, recorded on the day of administration, so that each dog received the same dose per kg of animal body weight.

[0068] Before each dose and between each animal, the catheters were rinsed with 5 mL of NaCl 0.9% and at least 20 mL of air. 1 mL blood samples were collected from the saphenous or cephalic veins of unanesthesised animals into sodium citrate tubes at various time points (usually pre-dose; 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose). Plasma was collected after centrifugation of the samples (10 min, 3000 g, +4° C.) and stored at −20° C. until analysis.

[0069] Pharmacokinetic studies after intravenous administration The pharmacokinetics of the poorly permeable molecules studied have been investigated after intravenous administration in order to calculate their pharmacokinetic parameters and bioavailability after oral and intraduodenal administration.

[0070] Dogs were fasted for 14 hours prior to each intravenous dose and fed 6 hours after dosing (during kinetic measurements). For intravenous administration, poorly permeable molecules were administered to dogs as a single bolus injection into a peripheral vein (saphenous or cephalic) using a plastic syringe.

[0071] The dose of the poorly permeable molecule administered was adjusted to each dog's body weight recorded on the day of dosing so that each dog received the same dose per kg of animal body weight. 1 mL blood samples were collected from the saphenous or cephalic vein of unanesthetized animals into sodium citrate tubes at various time points (usually pre-dose; 0.083, 0.166, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose). Plasma samples were prepared as detailed above (centrifugation and storage at -20°C until further analysis). EXAMPLES

[0072] Exemplary compositions of the formulations disclosed herein can be found in Table 4 below.

[0073] [Table 4]

[0074] The API was an antibody mimetic. Formulation F5 was equivalent to the placebo formulation F2. Formulations F6-F8 were used to test increasing drug loading.

[0075] Digestibility of the formulations disclosed herein: In the placebo formulation (F5), the release of free fatty acids was rapid with more than 85% of the digestible portion of the formulation being digested within less than 30 minutes releasing free fatty acids (mainly C8 and C10 fatty acids) that are known to enhance permeability across the intestinal membrane.

[0076] Formulation manufacturing: The placebo formulation is prepared at room temperature by adding the three excipients together in the given ratios (see table 4) and mixed with magnetic stirring until a single-phase solution is achieved (i.e., no phase separation after 24 hours without stirring).

[0077] The API selected in Example 2 is a protein of about 12 kDa, more specifically an antibody mimic. The lyophilized API was ground with a mortar and pestle before being added to the placebo formulation. The selected amount of API (see table 4) corresponding to the formulation to be manufactured is slowly added to the placebo solution with continuous stirring. After the entire amount of API is added, the resulting mixture is homogenized with stirring for at least 24 hours.

[0078] Table 3 below shows the bioavailability of proteins contained in the formulations disclosed herein after feeding to rats (formulations 6, 7, and 8) and dogs (formulation 7).

[0079] [Table 5]

[0080] Formulations 6, 7, and 8 were administered to rats via direct injection in the duodenal procedure. 250 mg of formulation was administered per rat (Sprague Dawley rats, n=4). This corresponds to 25, 50, and 100 mg of antibody per kg of body weight, respectively. Serum samples were collected at t=0, 3, 8, 24, 24, 72, 120, and 168 hours after administration. The antibody concentrations in the serum samples were quantified using an antibody-specific sandwich ELISA. The mean AUC, standard deviation, and bioavailability (F%) are listed in the table above. These values ​​are to be compared to the bioavailability equivalent to zero (API in PBS buffer) without any formulation.

[0081] A dog study was conducted with Formulation 7 in four fasted, non-naive male beagle dogs. The dogs were fasted 15-16 hours prior to dose administration, and food was returned approximately 1 hour after dosing. Each dog received five capsules per day for six consecutive days. The dose was approximately 10 mg antibody / kg animal per day. Serum samples were collected pre-dose on days 1, 2, 3, 4, 5, and 6, 2 hours post-dose on days 1, 2, 3, 4, 5, and 6, and 1, 2, 4, 8, 24, 48, 96, and 168 hours post-dose on day 6. Serum antibody concentrations were quantified using an antibody-specific sandwich ELISA. Results showed uptake (absorption) of antibody molecules in all four animals with some individual variability versus no absorption when the API was simply dissolved in PBS buffer. A summary of the PK results is presented in Table 11.

[0082] definition Unless otherwise defined, all technical terms, notations, and other technical and scientific terms or terminology used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some instances, terms having commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein need not be construed as representing a substantial departure from what is commonly understood in the art.

[0083] Reference herein to a value or parameter "about" includes (and describes) variations on the value or parameter itself. For example, a statement of "about X" includes the statement of "X." In addition, reference to the phrases "less than," "greater than," "at most," "at least," "less than or equal to," "greater than," or other similar phrases followed by a series of values ​​or parameters means that the phrase applies to each value or parameter in the series of values ​​or parameters. For example, a statement that a formulation has at most about 10 wt%, at most about 15 wt%, or at most about 20 wt% of a component means that the formulation has at most about 10 wt%, at most about 15 wt%, or at most about 20 wt% of the component.

[0084] As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the content clearly indicates otherwise. The term "and / or," as used herein, should also be understood to refer to and encompass any and all possible combinations of one or more of the associated listed items. It should be further understood that the terms "includes," "including," "comprises," and / or "comprising," as used herein, specify the presence of stated features, integers, steps, operations, elements, components, units, and / or groups thereof, but do not negate the presence or addition of one or more other features, integers, steps, operations, elements, components, units, and / or groups thereof.

[0085] This application discloses several numerical ranges herein. Because the disclosure can be implemented over the disclosed numerical ranges, the disclosed numerical ranges inherently support any range or value within the disclosed numerical ranges, including the endpoints, even if no explicit range limitations are stated verbatim herein.

[0086] The above description is presented to enable any person skilled in the art to make and use the disclosure, and is provided in the context of a particular application and its requirements. Various modifications to the preferred embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments and applications without departing from the spirit and scope of the disclosure. Thus, the disclosure is not intended to be limited to the embodiments shown, but is to be accorded the widest scope consistent with the principles and features disclosed herein.

Claims

1. A synthetic or natural poorly permeable molecule or its salt or solvate in an amount of 0.01-20 wt% of the total mass of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt% of the total mass of the formulation; and At least one lipophilic surfactant comprising a partial ester of a polyol and a fatty acid in an amount of 10 to 50 wt. % of the total mass of the formulation 13. A pharmaceutical formulation comprising:

2. 2. The formulation of claim 1, wherein the synthetic or natural poorly permeable molecule or a salt or solvate thereof is a BCS class III or class IV compound.

3. The formulation of claim 1, wherein the synthetic or natural poorly permeable molecule is a peptide or protein.

4. 4. The formulation of claim 3, wherein the peptide has 5 to 20 amino acids.

5. 5. The formulation of any one of claims 1 to 4, further comprising at least one hydrophilic surfactant having a hydrophilic lipophilic balance ("HLB") greater than 10 in an amount of 1 to 30 wt% of the total mass of the formulation.

6. 6. The formulation of claim 5, wherein the at least one hydrophilic surfactant is selected from the group consisting of polyoxyethylene (20) monooleate, PEG 8 caprylic / capric glyceride, PEG 6 caprylic / capric glyceride, poly(oxyethylene) (4) lauryl ether, and mixtures thereof.

7. 7. A formulation according to any one of claims 1 to 6, wherein the triglyceride of a fatty acid is a medium chain fatty acid.

8. 8. A formulation according to any one of claims 1 to 7, wherein the lipophilic surfactant comprises a mixture of mono- and diglycerides of medium chain fatty acids.

9. 9. The formulation according to any one of claims 1 to 8, which is free of water.

10. A delayed release pharmaceutical preparation comprising the formulation according to any one of claims 1 to 9, A delayed release pharmaceutical agent which is a coated agent whose release is pH dependent.

11. 11. A method for treating a patient comprising administering to a person in need thereof an effective amount of a formulation according to any one of claims 1 to 10.

Images